Prof. Prabhakar Rajan, Consultant Urological & Robotic Surgeon

Prof. Prabhakar Rajan

Consultant Urological & Robotic Surgeon

Book online
|

Prof. Prabhakar Rajan MBBChir MA (Cantab) PhD FRCS(Urol) FHEA

Consultant Urological & Robotic Surgeon

MBBChir MA (Cantab) PhD FRCS(Urol) FHEA

Prof. Prabhakar Rajan

Consultant Urological & Robotic Surgeon MBBChir MA (Cantab) PhD FRCS(Urol) FHEA

MBBChir MA (Cantab) PhD FRCS(Urol) FHEA

Areas of expertise

  • Prostate cancer risk assessment
  • Prostate biopsy (MRI-guided)
  • Robotic radical prostatectomy
  • Lower urinary tract symptoms
  • Testicular cancer

Address

About Prof. Prabhakar Rajan

GMC number: 4766584

Year qualified: 2000

Place of primary qualification: University of Cambridge

Professor Prabhakar Rajan is a leading urologist specialising in prostate cancer diagnostics, robotic surgery, and testicular cancer. He graduated from the University of Cambridge, completed surgical and urology training in Scotland, and undertook a fellowship in robotic surgery at the Karolinska Institutet and University Hospital in Stockholm, Sweden. Since 2015, he has been based at St Bartholomew’s Hospital (Barts Health NHS Trust) and University College London NHS Foundation Trust, where he leads the Uro-oncology service.

Prof. Rajan holds a PhD in prostate cancer from Newcastle University and completed post-doctoral research at the University of Glasgow and the CR-UK Beatson Institute. In 2012, he became the first urologist in Scotland to receive the Royal College of Surgeons of England/CR-UK Clinician Scientist Fellowship in Surgery. He now leads an internationally recognised cancer research group at the Barts Cancer Institute, Queen Mary University of London, and runs clinical trials exploring new treatments for prostate and testicular cancers.

He is a Fellow of the Royal College of Surgeons of England, the Higher Education Academy, and the Alan Turing Institute, and serves on national professional bodies for uro-oncology.

Outside of work, Prof. Rajan enjoys cycling, running, and travelling to remote destinations where he practises his Tamil—and occasionally Hindi and Spanish.

Areas of expertise

  • Benign prostate hyperplasia
  • Bladder cancer
  • Bladder neck incision
  • Blood in urine (haematuria)
  • Circumcision
  • Cystoscopy
  • Day case procedures
  • Epididymal cysts
  • Foreskin and scrotal conditions
  • Frenuloplasty (penis)
  • Germ cell testicular cancer
  • Hydrocelectomy
  • Hydrocoele (collection of fluid around the testicle)
  • MRI of prostate
  • Nerve sparing prostatectomy
  • Overactive bladder
  • Prostate biopsy (MRI-guided)
  • Prostate cancer risk assessment
  • Prostate cancer diagnostics
  • Prostatectomy (radical)
  • Prostatectomy (robotic)
  • Prostatectomy (turp)
  • Prostatitis (prostate swelling)
  • PSA testing
  • Retroperitoneal procedures
  • Retzius-sparing radical prostatectomy
  • Robotic surgery
  • Testicular cancer
  • Testicular lumps & swellings
  • Testicular pain
  • Transrectal ultrasound (TRUS)
  • Transurethral resection of a bladder tumour (TURBT)
  • Undescended testicle
  • Urethral and bladder neck sparing in prostatectomy
  • Urinary retention
  • Urinary tract infections (UTIs)
  • Urological cancers
  • Varicocele

Professional memberships

General Medical Council
British Association of Urological Surgeons
Royal College of Surgeons of England
British Medical Association (BMA)

Articles by Prof. Prabhakar Rajan

Emerging tools for the early detection of prostate cancer

Treatment de-escalation for metastatic good-risk seminoma with carboplatin AUC10: predictive factors and patterns of relapse

Therapy de escalation for testicular cancer (THERATEST): A multi centre observational cohort feasibility study of de escalation therapies for good prognosis stage II germ cell tumours

What Are the Barriers to Early Detection of Prostate Cancer for Black Men in the UK?

The prognostic value of LDH in patients with good risk metastatic seminoma treated with single agent carboplatin AUC10.

THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.

Interventions for patients with prostate cancer on active surveillance: a narrative review